---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-081943"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:06:22.501101+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio receives FDA Fast Track Designation for ADI-270 in advanced kidney cancer

## Summary
- ADI-270 granted Fast Track Designation for metastatic/advanced clear cell RCC after checkpoint and VEGF inhibitor therapy.
- This is Adicet's first gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors.
- ccRCC is the most common type of kidney cancer; Fast Track aims to expedite development and review.

## SEC filing metadata
- accession: 0000950170-24-081943
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024081943/0000950170-24-081943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024081943/acet-20240708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-081943
- JSON: https://secwatch.observer/filing/0000950170-24-081943.json
- Plain text: https://secwatch.observer/filing/0000950170-24-081943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.